TY - JOUR
T1 - Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils
AU - Stenson, W. F.
AU - Lobos, E.
PY - 1982
Y1 - 1982
N2 - Neutrophils metabolize arachidonic acid through the lipoxygenase pathway to 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) and 5,12-dihydroxy-6,8,10,14-eicosatraenoic acid (5,12 di-HETE). 5-HETE and 5,12 diHETE are potent chemotactic agents and are thought to have important roles in the inflammatory response. In this study we demonstrate that sulfasalazine, at concentrations found in the stool of patients being treated for ulcerative colitis, blocks the synthesis of both 5-HETE and 5,12 diHETE by human neutrophils. A sulfasalazine metabolite, 5-aminosalicylate, also blocks the synthesis of 5,12 diHETE.
AB - Neutrophils metabolize arachidonic acid through the lipoxygenase pathway to 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) and 5,12-dihydroxy-6,8,10,14-eicosatraenoic acid (5,12 di-HETE). 5-HETE and 5,12 diHETE are potent chemotactic agents and are thought to have important roles in the inflammatory response. In this study we demonstrate that sulfasalazine, at concentrations found in the stool of patients being treated for ulcerative colitis, blocks the synthesis of both 5-HETE and 5,12 diHETE by human neutrophils. A sulfasalazine metabolite, 5-aminosalicylate, also blocks the synthesis of 5,12 diHETE.
UR - http://www.scopus.com/inward/record.url?scp=0020072942&partnerID=8YFLogxK
U2 - 10.1172/JCI110474
DO - 10.1172/JCI110474
M3 - Article
C2 - 6120182
AN - SCOPUS:0020072942
SN - 0021-9738
VL - 69
SP - 494
EP - 497
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -